








Lranslational research: Is there a future?
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Tn this issue of the Journal, Tardif and associates1 from the Montreal Heart
Institute report the results of the double-blind, placebo-controlled MC-1 (car-
doxal) to Eliminate Necrosis Damage in Coronary Artery Bypass Grafting
MEND-CABG) trial conducted at 40 centers in the United States and Canada
etween April 2004 and July 2005. The MEND-CABG trial is a phase II study
ntended to evaluate the potential cardioprotective and neuroprotective effects of
yridoxal-5=-phosphate (cardoxal) in patients undergoing high-risk coronary artery
ypass grafting (CABG). Pyridoxal-5=-phosphate monohydrate (P-5=-P, or MC-1) is
naturally occurring metabolite of pyridoxine that acts as a purinergic receptor
ntagonist that blocks intracellular influx of calcium, thereby theoretically reducing
ell damage during episodes of ischemia and reperfusion.
It is important to realize that in the study design the authors and their statistical
olleagues decided on the primary and secondary end points on the basis of a careful
ccount of predictable event rates that would balance enrollment (number and
ssociated costs) with need to achieve believable statistical significance. The pri-
ary efficacy end point was the combined incidence of cardiovascular death,
onfatal myocardial infarction, and nonfatal cerebral infarction to day 30. Second-
ry efficacy end points included individual components of the combined end point,
rea under the curve of creatine kinase isoenzyme MB (CK-MB) within the first 24
ours after CABG, mortality from all causes, and composite and component end
oints to postoperative day 90. Myocardial infarction was defined in the indepen-
ent central core electrocardiographic laboratory as follows: (1) peak CK-MB value
reater than 50 ng/mL, or greater than 35 ng/mL with electrocardiographic evidence
f Q waves through postoperative day 4; (2) peak CK-MB greater than 25 ng/mL or
ew Q waves occurring after postoperative day 4; and (3) Q-wave or non–Q wave
yocardial infarction identified by investigator and confirmed by central core
aboratory.
P-5=-P did not significantly affect relative to placebo the prespecified composite
r component end points of cardiovascular death, myocardial infarction, and non-
atal cerebral infarction at either low (250 mg/d for 30 days) or high (750 mg/d for
0 days) doses. In a post hoc analysis in which the peak CK-MB level was increased
o 70 ng/mL or 100 ng/mL, there were significant reductions in the combined end
oints of death, nonfatal stroke, and nonfatal myocardial infarction with both dosing
egimens (250 and 750 mg/d). On the basis of this post hoc analysis, the authors
onclude, “Cardoxal may be particularly effective in preventing larger, more sig-
ificant perioperative infarcts.” They then suggest that a larger, better powered trial
s needed to evaluate further the cardioprotective effects of cardoxal.
There are a number of aspects of this trial that deserve comment. First, we
urrently live in a clinical world in which more and more emphasis is placed on
vidence-based medicine. In the pyramid of importance of clinically relevant
iterature, systematic reviews with meta-analysis are at the top of the pyramid,
ollowed by randomized, controlled, double-blind studies (followed by cohort
tudies, case controlled series, case series, case reports, ideas, editorials, opinions,
nimal research, and in vitro research).2 As surgeons, we are often criticized by our
edical colleagues for our lack of scientific credibility, because so much of our
eported literature revolves around retrospective case series. For that reason, pub-
ishing this type of well-designed, well-conducted, and well-reported trial is impor-
ant even if the results are essentially negative or only suggestive.











































































































LSecond, we must be extremely careful in drawing any
eaningful conclusions related to efficacy or accuracy in
uch a study from a post hoc analysis of the data as sug-
ested in the article. Numerous articles in the literature
escribe erroneous statistical conclusions on the basis of
eanalysis of the raw data or misrepresentation of the a
riori assumptions of a trial.3,4 Such post hoc analyses are
roblematic because they are undertaken after review of the
rial results. The clinical data set is then divided into sig-
ificantly different subgroups, and the statistical corrections
sually do not account for these additional analyses. When-
ver we increase the number of comparisons, some statis-
ical adjustment is necessary, such as a Bonferroni or Hoch-
erg correction5; otherwise, there is a much greater chance
f incurring a type I (or ) error (probability of incorrectly
ejecting the null hypothesis) or a type II (or ) error
probability of incorrectly accepting the null hypothesis).
his then would require P values considerably lower than
05 to be of any real value in any later analysis. In the post
oc analysis of the primary end points in this trial at the
eak CK-MB levels of 70 or 100 ng/mL, the P values were
etween .03 and .15, depending on the dose regimen. For
his reason, the results and analysis of the MEND study
ust be interpreted as being negative, and any meaningful
ost hoc analysis must be viewed with a degree of
kepticism.
This study can easily be compared with the recently
ublished Pexelizumab for Reduction of Infarction and
ortality in Coronary Artery Bypass Grafting Surgery
PRIMO-CABG) study, which looked at the impact of com-
lement inhibition (with a monoclonal antibody to the C5a
omplement complex called pexelizumab) during CABG.6
hen the PRIMO-CABG phase 3 study was published in
004, the primary end point was a reduction in the compos-
te end point of death or myocardial infarction. The PRIMO-
ABG trial was similar to the MEND-CABG trial in that
he a priori expected primary end point for PRIMO-CABG
as also not achieved. In a post hoc analysis, the PRIMO-
ABG investigators increased the CK-MB analysis to 75
g/mL (as is now being done in the MEND-CABG trial)
nd found a high-risk group of patients with more than two
isk factors who showed a “highly significant” benefit for
oth the primary and secondary end points. The PRIMO-
ABG investigators then went on to a second phase 3 trial,
s requested by the Food and Drug Administration, enroll-
ng more than 4000 additional patients worldwide. In this
econd phase 3 trial, the investigators redesigned the trial
ith the more restrictive primary and secondary end points
uggested in the first phase 3 publication. Absolutely no
fficacy or statistical significance was obtained in the final
tudy, and the drug was abandoned (unpublished data).
imilarly, a different preliminary phase 3 trial of pexeli-
umab during acute coronary interventions was suggestive v
410 The Journal of Thoracic and Cardiovascular Surgery ● Junf benefit after an initial post hoc analysis; however, the
ubsequent, definitive phase 3 trial was recently reported,
nd once again the drug was completely nonefficacious.7 I
trongly suspect that any further investigation looking at
ardoxal will follow a similar pattern and yield statistically
nsignificant results.
The final question relates to why promising preliminary
tudies in animals do not translate into similar clinical
esults in human beings. Clearly, inflammation has been
dentified in the last 20 years as a major pathophysiologic
ediator of sepsis, atherosclerosis, and ischemia–reperfu-
ion syndromes. This has led to a huge basic science liter-
ture looking at molecular and cellular mechanisms of
eperfusion injury, microvascular integrity, metabolic toler-
nce, coagulation abnormalities, and inflammatory dam-
ge.8 What is most interesting is the almost total lack of
fficacy seen in clinical trials attempting to translate the
asic science into clinical practice.6,7 The obvious conclu-
ion is that we have made little or no clinical advance in
ranslational research in trauma, sepsis, atherosclerosis, or
ny ischemia–reperfusion state.9 The obvious question,
hen, is why? Certainly, the inflammatory and coagulation
ascades as we now understand them are highly complex,
nterconnected pathways, networks, and molecular systems
hat are teleologically redundant as a result of eons and eons
f inflammatory challenge and genetic evolution. What may
e more important are concepts that are now based on recent
nderstandings of human genomics and proteonomics.10
ariable responses to pharmacologic agents seem to have a
ore complex origin involving the interplay between mul-
iple genetic factors (genes and their products) and nonge-
etic factors (environmental influences). We now under-
tand that genetic variations in the human population,
ncluding single-nucleotide polymorphisms, small deletions
nd insertions, and other structural differences (including
aplotypes, sets of genes inherited as units) are very com-
on and may be critical to our understanding of the rela-
ionships between genotype and biologic function. Such
enetic variation may account for the tremendous clinical
ariation and how human beings respond to various similar
nsults such as ischemia–reperfusion, sepsis, and shock. It
ay also explain why it is so difficult to find efficacy in
ltering a single cellular or molecular target. Simply target-
ng a single receptor at the beginning of the inflammatory
ascade or targeting an upregulated new protein at the end
f the cascade, which might alter the cellular phenotype,
eems increasingly unlikely to be efficacious. Whether mul-
iple targets will be synergistic, leading to a predictable
linical benefit, or whether there may be critical central
ontrol points within the cellular communication pathways
such as signal transduction pathways or transcriptional



















Lesponses to insults and to new therapy and why there are
uch different physiologic responses in different species.
Looking beyond the well-presented results of this study
ill yield insights for all of us as we look to the future of
ranslational research. If we are to make cardiopulmonary
ypass and cardiothoracic and vascular surgery safer and
mprove outcomes, we will have to look beyond technology
nd understand science. Certainly studies such as the one
ublished by the MEND-CABG group should stimulate all
urgeons to look at the critical importance of basic science
o our increasingly complex clinical challenges.
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